{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:59:06Z","timestamp":1793303946242,"version":"4.5.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi231424-4\"><jats:title>Importance<\/jats:title><jats:p>Many multimodality treatment regimens exist for gastric adenocarcinoma, including neoadjuvant vs adjuvant chemotherapy, radiation, or both. Neoadjuvant therapy is recommended in the United States for patients with locally advanced gastric cancer; however, it is unknown whether the outcomes of neoadjuvant therapy are associated with race and ethnicity.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231424-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the differences in outcomes by race and ethnicity of patients with noncardia gastric cancer undergoing surgical procedures with and without neoadjuvant therapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231424-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective cohort study examined the National Cancer Database from the American College of Surgeons for patients with clinical stage II or III gastric adenocarcinoma, excluding gastric cardia tumors, undergoing surgical resection procedures from January 2006 to December 2019. Statistical analysis was performed from December 2021 to May 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231424-7\"><jats:title>Exposure<\/jats:title><jats:p>Patients were stratified by race and ethnicity, and their outcomes were analyzed for those who received and did not receive neoadjuvant therapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231424-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The Cox proportional hazard model was used to compare overall survival (OS) between racial and ethnic groups (Asian, Black, Hispanic, and White) overall and according to receipt of neoadjuvant therapy. Among those who received neoadjuvant therapy, proportional differences in pathological responses were calculated in each group.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231424-9\"><jats:title>Results<\/jats:title><jats:p>Among a total of 6938 patients in the cohort, 4266 (61.4%) were male; mean (SD) age was 65.9 (12.8) years; 1046 (15.8%) were Asian, 1606 (24.3%) were Black, 1175 (17.8%) were Hispanic, and 3540 (53.6%) were White. Compared with other races and ethnicities, the group of White patients had significantly more who were 65 years or older with more comorbidities. White patients underwent surgical resection procedures alone without neoadjuvant or adjuvant therapy more frequently than other races and ethnicities. Asian and Black patients had the highest proportion of being downstaged or achieving pathological complete response after neoadjuvant therapy. In multivariate models, perioperative chemotherapy was associated with improved OS (HR, 0.79 [95% CI, 0.69-0.90]), whereas number of positive lymph nodes and surgical margins were associated with the largest decreases in OS. Asian and Hispanic race and ethnicity were associated with significantly improved OS compared with Black and White races (eg, Asian patients: HR, 0.64 [95% CI, 0.58-0.72]; and Hispanic patients: HR, 0.77 [95% CI, 0.69-0.85]). Black race was associated with improved OS compared with White race when receiving neoadjuvant therapy (HR, 0.78 [95% CI, 0.67-0.90]).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231424-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this large nationwide cohort study of survival outcomes among patients with resected clinical stage II or III gastric cancer, there were significant differences in response to treatment and OS between different racial and ethnic groups.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.49026","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T16:01:15Z","timestamp":1703174475000},"page":"e2349026","source":"Crossref","is-referenced-by-count":11,"title":["Survival Outcomes and Patterns of Care for Stage II or III Resected Gastric Cancer by Race and Ethnicity"],"prefix":"10.1001","volume":"6","author":[{"given":"S. Peter","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, City of Hope Medical Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara H.","family":"Keshavjee","sequence":"additional","affiliation":[{"name":"Department of Surgery, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Surgery, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Surgery, Roger Williams Medical Center and Boston University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"issue":"1","key":"zoi231424r1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.v73.1","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"zoi231424r2","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s10620-011-1642-x","article-title":"Gastric cancer: two epidemics?","volume":"56","author":"Correa","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"6","key":"zoi231424r3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/jim-2017-000413","article-title":"Racial disparities in stage-specific gastric cancer: analysis of results from the Surveillance Epidemiology and End Results (SEER) program database.","volume":"65","author":"Zhang","year":"2017","journal-title":"J Investig Med"},{"issue":"19","key":"zoi231424r4","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","article-title":"Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.","volume":"30","author":"Smalley","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi231424r5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial?.","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi231424r6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"issue":"10184","key":"zoi231424r7","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial.","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"zoi231424r8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41416-020-01038-6","article-title":"Cancer health disparities in racial\/ethnic minorities in the United States.","volume":"124","author":"Zavala","year":"2021","journal-title":"Br J Cancer"},{"issue":"7517","key":"zoi231424r9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma.","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"2","key":"zoi231424r10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/cncr.v116:2","article-title":"Variations in gastric cancer care: a trend beyond racial disparities.","volume":"116","author":"Al-Refaie","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"zoi231424r11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/cncr.v124.5","article-title":"Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: analysis of the National Cancer Data Base, 2006-2014.","volume":"124","author":"Ikoma","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"zoi231424r12","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/jso.v123.8","article-title":"Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer.","volume":"123","author":"Rajabnejad","year":"2021","journal-title":"J Surg Oncol"},{"issue":"9","key":"zoi231424r13","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay4211","article-title":"Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy.","volume":"6","author":"Li","year":"2020","journal-title":"Sci Adv"},{"issue":"4","key":"zoi231424r14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time.","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"zoi231424r15","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.ejso.2020.05.014","article-title":"Oncologic and surgical outcomes for gastric cancer patients undergoing gastrectomy differ by race in the United States.","volume":"46","author":"Tee","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"zoi231424r16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1245\/s10434-016-5645-x","article-title":"Race is a risk for lymph node metastasis in patients with gastric cancer.","volume":"24","author":"Ikoma","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"zoi231424r17","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1007\/s11605-014-2590-5","article-title":"Race\/ethnicity is predictive of lymph node status in patients with early gastric cancer.","volume":"18","author":"Fukuhara","year":"2014","journal-title":"J Gastrointest Surg"},{"issue":"11","key":"zoi231424r18","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s11605-019-04138-8","article-title":"Evaluating dissemination of adequate lymphadenectomy for gastric cancer in the USA.","volume":"23","author":"Villano","year":"2019","journal-title":"J Gastrointest Surg"},{"issue":"9","key":"zoi231424r19","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1245\/s10434-015-4388-4","article-title":"Comparison of gastric cancer survival between Caucasian and Asian patients treated in the United States: results from the Surveillance Epidemiology and End Results (SEER) database.","volume":"22","author":"Wang","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"28","key":"zoi231424r20","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1200\/JCO.2011.35.8028","article-title":"Long-term survivors of gastric cancer: a California population-based study.","volume":"30","author":"Kunz","year":"2012","journal-title":"J Clin Oncol"},{"key":"zoi231424r21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijsu.2018.01.008","article-title":"Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. meta-analysis of randomized trials.","volume":"51","author":"Coccolini","year":"2018","journal-title":"Int J Surg"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2813183\/wu_2023_oi_231424_1702485706.87818.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T16:01:18Z","timestamp":1703174478000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2813183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.49026","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}